Cargando…

High Platelet Reactivity in Patients with Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention: Randomised Controlled Trial Comparing Prasugrel and Clopidogrel

BACKGROUND: Prasugrel is more effective than clopidogrel in reducing platelet aggregation in acute coronary syndromes. Data available on prasugrel reloading in clopidogrel treated patients with high residual platelet reactivity (HRPR) i.e. poor responders, is limited. OBJECTIVES: To determine the ef...

Descripción completa

Detalles Bibliográficos
Autores principales:	Geisler, Tobias, Booth, Jean, Tavlaki, Elli, Karathanos, Athanasios, Müller, Karin, Droppa, Michal, Gawaz, Meinrad, Yanez-Lopez, Monica, Davidson, Simon J., Stables, Rod H., Banya, Winston, Zaman, Azfar, Flather, Marcus, Dalby, Miles
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2015
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4552627/ https://www.ncbi.nlm.nih.gov/pubmed/26317618 http://dx.doi.org/10.1371/journal.pone.0135037

Ejemplares similares

Evaluation of Clinical Risk Factors to Predict High On-Treatment Platelet Reactivity and Outcome in Patients with Stable Coronary Artery Disease (PREDICT-STABLE)
por: Droppa, Michal, et al.
Publicado: (2015)

Comparison of prasugrel and clopidogrel in patients with acute coronary syndrome undergoing percutaneous coronary intervention
por: Norgard, Nicholas B, et al.
Publicado: (2009)

Macrophage Migration Inhibitory Factor Is Enhanced in Acute Coronary Syndromes and Is Associated with the Inflammatory Response
por: Müller, Iris I., et al.
Publicado: (2012)

Real-world comparison of clopidogrel, prasugrel and ticagrelor in patients undergoing primary percutaneous coronary intervention
por: Krishnamurthy, Arvindra, et al.
Publicado: (2019)

Prasugrel switching from clopidogrel after percutaneous coronary intervention for acute coronary syndrome in Taiwanese patients: an analysis of safety and efficacy
por: Liu, Ping-Yen, et al.
Publicado: (2021)

Correction: Real-world comparison of clopidogrel, prasugrel and ticagrelor in patients undergoing primary percutaneous coronary intervention
Publicado: (2019)

De-escalation therapy after acute coronary syndrome: is it reasonable to switch from prasugrel (or ticagrelor) to clopidogrel early?
por: Masiero, Giulia, et al.
Publicado: (2020)

Short-term Safety and Mid-term Efficacy of Prasugrel Versus Clopidogrel in Patients Undergoing Percutaneous Coronary Intervention
por: Koyabu, Yota, et al.
Publicado: (2019)

Use of Clopidogrel, Prasugrel, or Ticagrelor and Patient Outcome after Acute Coronary Syndrome in Austria from 2015 to 2017
por: Rezaei, Safoura Sheikh, et al.
Publicado: (2020)

The Pharmacokinetics and Pharmacodynamics of Prasugrel and Clopidogrel in Healthy Japanese Volunteers
por: Umemura, Kazuo, et al.
Publicado: (2016)

Time Course of Ischemic and Bleeding Burden in Elderly Patients With Acute Coronary Syndromes Randomized to Low‐Dose Prasugrel or Clopidogrel
por: Crimi, Gabriele, et al.
Publicado: (2019)

Differential Impact of Clinical and Genetic Factors on High Platelet Reactivity in Patients with Coronary Artery Disease Treated with Clopidogrel and Prasugrel
por: Saito, Yuichi, et al.
Publicado: (2022)

Long-term use of clopidogrel versus ticagrelor or prasugrel in patients with acute myocardial infarction after percutaneous coronary intervention
por: Kim, Yuri, et al.
Publicado: (2023)

Successful Prasugrel Rescue Therapy in Clopidogrel Resistant Patients Who Had Recurrent Stent Thrombosis of Drug-Eluting-Stent: The Role of Prasugrel in Clopidogrel Nonresponders
por: Lee, Seung-Hyun, et al.
Publicado: (2013)

Lower Loading Dose of Prasugrel Compared with Conventional Loading Doses of Clopidogrel and Prasugrel in Korean Patients Undergoing Elective Coronary Angiography: A Randomized Controlled Study Evaluating Pharmacodynamic Efficacy
por: Lee, Dong Hyun, et al.
Publicado: (2014)

Differential impact of diabetes mellitus on antiplatelet effects of prasugrel and clopidogrel
por: Niijima, Satoshi, et al.
Publicado: (2018)

Reduction in recurrent cardiovascular events with prasugrel compared with clopidogrel in patients with acute coronary syndromes from the TRITON-TIMI 38 trial
por: Murphy, Sabina A., et al.
Publicado: (2008)

Comparison of Clopidogrel With Prasugrel and Ticagrelor in Patients With Acute Coronary Syndrome: Clinical Outcomes From the National Cardiovascular Database ACTION Registry
por: Khayata, Mohamed, et al.
Publicado: (2017)

Effects of clopidogrel, prasugrel and ticagrelor on prevention of stent thrombosis in patients underwent percutaneous coronary intervention: A network meta‐analysis
por: Chen, Wenwen, et al.
Publicado: (2021)

Comparative Effectiveness of Ticagrelor, Prasugrel, and Clopidogrel for Secondary Prophylaxis in Acute Coronary Syndrome: A Propensity Score‐Matched Cohort Study
por: Kumar, Arun, et al.
Publicado: (2022)

Prasugrel for the treatment of patients with acute coronary syndrome
por: Marzot, Filippo, et al.
Publicado: (2009)

Prasugrel Results in Higher Decrease in High-Sensitivity C-Reactive Protein Level in Patients Undergoing Percutaneous Coronary Intervention Comparing to Clopidogrel
por: Hajsadeghi, Shokoufeh, et al.
Publicado: (2016)

Ischemic and Bleeding Events Among Patients With Acute Coronary Syndrome Associated With Low-Dose Prasugrel vs Standard-Dose Clopidogrel Treatment
por: Shoji, Satoshi, et al.
Publicado: (2020)

Low-Dose Prasugrel in Patients with Resistance to Clopidogrel for the Treatment of Cerebral Aneurysms
por: Lee, Dongwhane, et al.
Publicado: (2018)

C5 Variant rs10985126 is Associated with Mortality in Patients with Symptomatic Coronary Artery Disease
por: Henes, Jessica Kristin, et al.
Publicado: (2021)

Effects of Clopidogrel, Prasugrel and Ticagrelor on Microvascular Function and Platelet Reactivity in Patients With Acute Coronary Syndrome Undergoing Coronary Artery Stenting. A Randomized, Blinded, Parallel Group Trial
por: Schnorbus, Boris, et al.
Publicado: (2021)

Randomized Comparison of the Platelet Inhibitory Efficacy between Low Dose Prasugrel and Standard Dose Clopidogrel in Patients Who Underwent Percutaneous Coronary Intervention
por: Jin, Han-Young, et al.
Publicado: (2014)

Novel Oral P2Y12 Inhibitor Prasugrel vs. Clopidogrel in Patients with Acute Coronary Syndrome: Evidence Based on 6 Studies
por: Jia, Min, et al.
Publicado: (2015)

Effects of switching from clopidogrel to prasugrel at the chronic phase after coronary stenting on antiplatelet action and vascular endothelial function: Switch-Pras study
por: Masuyama, Taiki, et al.
Publicado: (2020)

Efficacy and safety comparing prasugrel/ticagrelor and clopidogrel in Hong Kong post‐acute coronary syndrome patients–A 10‐year cohort study
por: Lam, Amy S. M., et al.
Publicado: (2021)

Biocatalytic Syntheses of Antiplatelet Metabolites of the Thienopyridines Clopidogrel and Prasugrel Using Fungal Peroxygenases
por: Kiebist, Jan, et al.
Publicado: (2021)

Genetic variation of CYP2C19 affects both pharmacokinetic and pharmacodynamic responses to clopidogrel but not prasugrel in aspirin-treated patients with coronary artery disease
por: Varenhorst, Christoph, et al.
Publicado: (2009)

Post percutaneous coronary interventional adverse cardiovascular outcomes and bleeding events observed with prasugrel versus clopidogrel: direct comparison through a meta-analysis
por: Bundhun, Pravesh Kumar, et al.
Publicado: (2018)

Comparison of prasugrel and clopidogrel reloading on high platelet reactivity in clopidogrel-loaded patients undergoing percutaneous coronary intervention (PRAISE-HPR): a study protocol for a prospective randomized controlled clinical trial
por: Lee, Dong-Hyun, et al.
Publicado: (2013)

Assessment of data quality in an international multi-centre randomised trial of coronary artery surgery
por: Krzych, Lukasz J, et al.
Publicado: (2011)

Comparison of lower loading dose of prasugrel with conventional loading dose of prasugrel in Indian patients undergoing percutaneous coronary interventions
por: Kumari, Priti, et al.
Publicado: (2018)

Pharmacy Benefit Spending Poised to Increase for Antithrombotic Drug Therapy--Prasugrel Versus Clopidogrel
por: Curtiss, Frederic R.
Publicado: (2009)

Effects of clopidogrel, prasugrel and ticagrelor on endothelial function, inflammatory and oxidative stress parameters and platelet function in patients undergoing coronary artery stenting for an acute coronary syndrome. A randomised, prospective, controlled study
por: Schnorbus, Boris, et al.
Publicado: (2014)

Improving outcomes in patients undergoing percutaneous coronary intervention: role of prasugrel
por: Motovska, Zuzana, et al.
Publicado: (2009)

Impaired Myocardial Function Is Prognostic for Severe Respiratory Failure in the Course of COVID-19 Infection
por: Petersen-Uribe, Alvaro, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_r86r175cu86ubg5j71alahqf6d